Skip to content
DataLookout
Menu

NCT06549790

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The decision about study closure has not been based on safety profile or clinical data of NMS- 03597812 but for strategic decisions regarding the company's assets. Show 6 more changesShow less
    • Eligibility criteria expanded, about 31 words
    • Final enrollment: 23 participants (planned 124)
    • Primary completion date changed from estimate of Sep 15, 2029 to Sep 24, 2026
    • Study sites: 7 to 6
    • Study completion date changed from estimate of May 15, 2030 to Oct 5, 2026
    • Secondary endpoints: details revised at 4 of 22 entries
  2. Minor Site details revised at 1 of 7 sitesv10
  3. Minor Study sites: 6 to 7v9
  4. Minor Study sites: 4 to 6v7
  5. Minor Study sites: 3 to 4v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 2 to 3v5
  2. Minor Study sites: 1 to 2
    • Start date changed from estimate of Oct 5, 2024 to Oct 16, 2024
    v4
  3. Notable Start date: Aug 2024 to Oct 5, 2024v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase Ia (escalation) - Number of Participants with Adverse Events (AEs)
Timeframe: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 13 months)
Phase Ib (expansion) - Complete Remission (CR) rate
Timeframe: From date of treatment initiation up to hematological relapse (Approximately 12 months)

Secondary (22)

Phase Ia - Complete remission (CR) rate
Phase Ia - Maximum concentration (Cmax) of NMS-0597812
Phase Ia - Related time of achievement of occurrence of Cmax (tmax) of NMS-0597812
Trough concentration (Cτ) area under concentration versus time up to 24 hours (dosing interval) of NMS-0597812
Phase Ia - Half-life of the terminal phase (t½,z) of NMS-0597812
Show 17 moreShow less
Phase Ia - Plasma clearance (CL) of NMS-0597812
Phase Ia - Volume of distribution (Vss) of NMS-0597812
Phase Ia - Accumulation ratio (Rac) of NMS-0597812
Phase Ia - Renal clearance (CLR) of NMS-03597812 excreted in urine (data permitting)
Phase Ia - Cumulative amount recovered unchanged in the urine (Ae) of NMS-03597812 (data permitting)
Phase Ia - Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03597812 (data permitting)
Phase Ib - Complete remission (CR) + complete remission with partial hematologic recovery (CRh) rate
Phase Ib - Complete remission (CR) + Complete remission with incomplete hematologic recovery (CRi) rate
Phase Ib - Complete remission (CR) + Complete remission with partial hematologic recovery (CRh) + complete remission with incomplete hematologic recovery (CRi) rate
Phase Ib - Overall Response Rate (ORR: CR + CRh + CRi + MLFS + PR)
Phase Ib - Overall Survival (OS)
Phase Ib - Duration of Response (DoR)
Phase Ib - Event-Free Survival (EFS)
Phase Ib - Relapse-free Survival (RFS)
Phase Ib - Proportion of patients bridged to hemopoietic stem cell transplantation (HSCT)
Phase Ib - Rate of conversion from transfusion-dependence to transfusion independence
Phase Ib - AE frequency and severity

Arms and interventions

NMS-03597812Experimental

Dose escalation (Phase Ia): Administered orally once daily (28 consecutive days) in repeated 4-week cycles. Each cycle is 28 days. Expansion cohorts (Phase Ib, Cohorts A and B): The dose expansion may comprise up to a total of 2 single arms of NMS-03597812 as single agent: * Cohort A: in patients with TP53mt relapsed/refractory acute myeloid leukemia (R/R AML) prior unfit to intensive chemotherapy (IC) who have exhausted standard treatment options * Cohort B: in prior fit or unfit patients to IC with TP53wt R/R AML who have exhausted standard treatment options Backfill cohorts: Optional backfill cohorts may be opened at any time during the conduct of the trial to further evaluate the following items: NMS-03597812 dosing alone, pharmacokinetic (PK), drug-drug interactions, food effects, biomarkers and QTc for NMS-03597812 as single agent.

Drugs: NMS-03597812

Sites

6 sites in 1 country